PharmaVoice Feb 17, 2026 More drugmakers are turning to cancer combos. Will it help patients live longer?
PharmaVoice Feb 12, 2026 Lilly’s $2.4B bet on off-the-shelf cell therapy is part of a wider Big Pharma shift
PharmaVoice Feb 11, 2026 A protein model designed for space could expand pharma’s definition of ‘druggability’
PharmaVoice Feb 3, 2026 Investors crave safer, market-ready biotech bets, widening the early-stage funding gap